Scarica l'app Stockscreener
4.40
13.04%
-0.66
Dopo l'orario di chiusura:
4.37
-0.03
-0.68%
Precedente Chiudi:
$5.06
Aprire:
$5.02
Volume 24 ore:
1.82M
Relative Volume:
1.79
Capitalizzazione di mercato:
$306.40M
Reddito:
-
Utile/perdita netta:
$-297.11M
Rapporto P/E:
-0.8478
EPS:
-5.19
Flusso di cassa netto:
$-216.95M
1 W Prestazione:
-15.55%
1M Prestazione:
-18.67%
6M Prestazione:
-75.43%
1 anno Prestazione:
-50.45%
Intervallo 1D:
$4.345
$5.075
Intervallo di 1 settimana:
$4.345
$6.98
Portata 52W:
$4.345
$19.71
Phathom Pharmaceuticals Inc Stock (PHAT) Company Profile
Nome
Phathom Pharmaceuticals Inc
Settore
Industria
Telefono
(877) 742-8466
Indirizzo
100 CAMPUS DRIVE,, FLORHAM PARK, NJ
Confronta PHAT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PHAT
Phathom Pharmaceuticals Inc
|
4.40 | 306.40M | 0 | -297.11M | -216.95M | -5.19 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.01 | 128.40B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
744.83 | 81.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
571.00 | 34.69B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
233.07 | 30.17B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beone Medicines Ltd Adr
|
242.66 | 26.02B | 3.32B | -860.46M | -1.04B | -8.32 |
Phathom Pharmaceuticals Inc Stock (PHAT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-14 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-05-03 | Iniziato | Stifel | Buy |
| 2024-01-05 | Reiterato | Needham | Buy |
| 2023-08-09 | Iniziato | H.C. Wainwright | Buy |
| 2023-05-11 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2023-03-13 | Iniziato | Craig Hallum | Buy |
| 2022-10-21 | Iniziato | Jefferies | Buy |
| 2022-05-06 | Downgrade | Evercore ISI | Outperform → In-line |
| 2021-05-12 | Aggiornamento | Goldman | Sell → Neutral |
| 2021-02-17 | Iniziato | BMO Capital Markets | Outperform |
| 2021-02-02 | Iniziato | Guggenheim | Buy |
| 2020-06-26 | Downgrade | Goldman | Neutral → Sell |
| 2019-11-20 | Iniziato | Evercore ISI | Outperform |
| 2019-11-19 | Iniziato | Goldman | Neutral |
| 2019-11-19 | Iniziato | Jefferies | Buy |
| 2019-11-19 | Iniziato | Needham | Buy |
Mostra tutto
Phathom Pharmaceuticals Inc Borsa (PHAT) Ultime notizie
Phathom Pharmaceuticals’ Earnings Call: Growth and Challenges - TipRanks
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q4 2024 Earnings Call Transcript - Insider Monkey
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Position Boosted by Rhumbline Advisers - Defense World
Phathom Pharmaceuticals (NASDAQ:PHAT) Earns Buy Rating from HC Wainwright - Defense World
Phathom Pharmaceuticals (NASDAQ:PHAT) Earns Buy Rating from Needham & Company LLC - Defense World
Phathom Pharmaceuticals price target lowered to $12 from $18 at Goldman Sachs - TipRanks
H.C. Wainwright maintains $28 target on Phathom Pharma stock By Investing.com - Investing.com Canada
H.C. Wainwright maintains $28 target on Phathom Pharma stock - Investing.com
Phathom Pharmaceuticals Inc (PHAT) Q4 2024 Earnings Call Highlights: FDA Approval Boosts ... - Yahoo Finance
Phathom Pharmaceuticals Reports Strong Growth with VOQUEZNA - TipRanks
Phathom Pharmaceuticals: Strong Performance and Optimistic Outlook Amidst Patent Uncertainty - TipRanks
Stifel maintains Buy on Phathom stock with $28 target - Investing.com India
Stifel maintains Buy on Phathom stock with $28 target By Investing.com - Investing.com South Africa
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q4 Loss, Tops Revenue Estimates - MSN
Earnings call transcript: Phathom Pharma Q4 2024 sees 81% revenue rise - Investing.com UK
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - GlobeNewswire
Phathom Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Phathom Pharmaceuticals, Inc. SEC 10-K Report - TradingView
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - GlobeNewswire Inc.
Phathom Pharmaceuticals Inc. (PHAT) reports earnings - Quartz
Earnings To Watch: Phathom Pharmaceuticals Inc (PHAT) Reports Q4 2024 Result - GuruFocus.com
Phathom Pharmaceuticals stock hits 52-week low at $5.21 - Investing.com
Phathom Pharmaceuticals stock hits 52-week low at $5.21 By Investing.com - Investing.com Canada
(PHAT) Investment Analysis and Advice - Stock Traders Daily
Phathom Pharmaceuticals (PHAT) Expected to Announce Earnings on Thursday - MarketBeat
Cantor Fitzgerald Upgrades Phathom Pharmaceuticals (NASDAQ:PHAT) to Strong-Buy - MarketBeat
Phathom Pharmaceuticals (PHAT) Projected to Post Quarterly Earnings on Thursday - Defense World
Phathom Pharmaceuticals to Report Fourth Quarter and Full - GlobeNewswire
Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 6, 2025 - The Manila Times
Phathom Pharmaceuticals to Host Conference Call on March 6, 2025, for Fourth Quarter and Full Year 2024 Financial Results - Nasdaq
Can Phathom's VOQUEZNA Sales Drive Q4 Growth? Earnings Call Set for March 6 - StockTitan
How to Take Advantage of moves in (PHAT) - Stock Traders Daily
Phathom Pharmaceuticals CFO Molly Henderson sells shares worth $43,370 - MSN
Cantor Fitzgerald Begins Coverage on Phathom Pharmaceuticals (NASDAQ:PHAT) - MarketBeat
Phathom spikes as Cantor Fitzgerald bullish on IP claims - MSN
Cantor Fitzgerald Initiates Coverage on Phathom Pharmaceuticals (NASDAQ:PHAT) - Defense World
Phathom stock gains after Cantor bullish view (PHAT:NASDAQ) - Seeking Alpha
symbol__ Stock Quote Price and Forecast - CNN
Phathom Pharmaceuticals initiated at Cantor Fitzgerald on ‘significant’ upside - TipRanks
Cantor Fitzgerald Initiates Coverage on Phathom Pharmaceuticals With Overweight Rating, $23 Price Target - Marketscreener.com
Taking a Closer Look At Phathom Pharmaceuticals Inc (PHAT) Following Its Recent Trade - Knox Daily
Phathom Pharmaceuticals (PHAT) Stock Price, News & Analysis - MarketBeat
Stifel maintains $28 target on Phathom Pharmaceuticals stock - MSN
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Shares Bought by Jennison Associates LLC - MarketBeat
Stifel maintains $28 target on Phathom Pharmaceuticals stock By Investing.com - Investing.com Canada
Phathom Pharmaceuticals Inc (PHAT) Stock: Assessing the Risk and Reward - The News Heater
The Future of Phathom Pharmaceuticals Inc: Analyzing PHAT - The InvestChronicle
Phathom Pharmaceuticals Inc [PHAT] CFO and CBO makes an insider sale of 6,583 shares worth $43371.0. - Knox Daily
Closing Strong: Phathom Pharmaceuticals Inc (PHAT) Ends at 5.63, Down -6.01 from Last Close - The Dwinnex
A stock that deserves closer examination: Phathom Pharmaceuticals Inc (PHAT) - US Post News
Phathom Pharmaceuticals Inc Azioni (PHAT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.98%
8.97%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):